



SUPPLEMENTARY FIGURE. Proportion of invasive pneumococcal disease cases by vaccine-type and vaccination coverage among adults aged 19–64 years (A) and ≥65 years (B) with an indication for pneumococcal vaccination* — United States 2018–2022

A. Age 19–64 years with a risk-based indication

B. Age ≥65 years



PCV20/ non-PCV21 serotype: 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F, 15B
 PCV20/ in-PCV21 serotypes: 3, 6A, 7F, 19A, 22F, 33F, 8, 10A, 11A, 12F, +6C
 PCV21/ non-PCV20 serotypes: 9N, 17F, 20, 15A, 15C, 16F, 23A, 23B, 24F, 31, 35B

Abbreviations: IPD = invasive pneumococcal disease; NVT = nonvaccine serotype; PCV = pneumococcal conjugate vaccine; PCV20 = 20-valent PCV; PCV21 = 21-valent PCV

* Gierke R. ACIP Presentation Slides: February 28–29, 2024 Meeting. Current Epidemiology of Pneumococcal Disease Among Adults, United States. Available from: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-02-28-29/02-Pneumococcal-Gierke-508.pdf>

